Is Synchrony’s Earnings Jump and $6.5 Billion Buyback Shaping the Investment Case for SYF?

In April 2026, Synchrony Financial reported higher first-quarter net interest income of US$4,635 million and net income of US$805 million, while its board approved a quarterly dividend of US$0.30 per share, declared preferred dividends, authorized a new US$6.50 billion share repurchase program, and outlined plans to lift the common dividend to US$0.34 from the third quarter of 2026. Alongside these shareholder return moves, Synchrony expanded its retail partner ecosystem by launching new co-branded and private-label credit card programs with Chico’s FAS brands and RH, integrating its PRISM credit decisioning platform to support more personalized lending and loyalty-driven customer engagement. We’ll now examine how Synchrony’s stronger earnings and expanded buyback authorization may influence its existing investment narrative and risk profile.

Rare earth metals are the new gold rush. Find out which 32 stocks are leading the charge.

Synchrony Financial Investment Narrative Recap

To own Synchrony, you generally need to believe its partner-centric card model and digital underwriting can keep generating solid earnings while managing credit risk and regulatory pressure. The latest results and capital return moves support that view in the near term, but the key catalyst is still whether new and renewed partnerships translate into higher receivables, while the biggest risk remains that cautious consumer spending keeps purchase volumes and loan growth subdued. The April news does not remove that tension.

The new US$6.50 billion buyback authorization is especially relevant here, because it combines with mid single digit dividend increases to concentrate more of Synchrony’s earnings power in each remaining share. That capital return profile may appeal to investors who already see value in the shares, but it also raises the stakes if earnings come under pressure from weaker purchase volumes or tighter regulation, since there is less room for error once so much capital has gone back out the door.

Yet while these shareholder returns look appealing, investors should be aware that Synchrony’s high bad loan ratio and partnership concentration mean...

Read the full narrative on Synchrony Financial (it's free!)

Synchrony Financial's narrative projects $16.5 billion revenue and $3.3 billion earnings by 2028. This requires 21.7% yearly revenue growth and roughly a $0.1 billion earnings increase from $3.2 billion today.

Uncover how Synchrony Financial's forecasts yield a $90.26 fair value, a 18% upside to its current price.

Exploring Other PerspectivesSYF 1-Year Stock Price Chart

Some of the lowest ranked analysts paint a far more cautious picture, assuming revenue only reaches about US$16.2 billion and earnings fall to roughly US$2.7 billion, so if you are weighing the new earnings and buyback news against those expectations, it is worth remembering that views on Synchrony’s future can differ widely and may shift again as fresh data comes through.

Story Continues

Explore 7 other fair value estimates on Synchrony Financial - why the stock might be worth 7% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

A great starting point for your Synchrony Financial research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision. Our free Synchrony Financial research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Synchrony Financial's overall financial health at a glance.

No Opportunity In Synchrony Financial?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SYF.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments